The DOI matches its Crossref record; 123 of the 123 references it cites were found in a registry or an index.
Addressing the challenges of pancreatic cancer: Future directions for improving outcomes
Open accessAbstract
Pancreatic ductal adenocarcinoma (PDAC), which accounts for more than 90% of all pancreatic tumours, is a devastating malignancy with an extremely poor prognosis, as shown by a 1-year survival rate of around 18% for all stages of the disease. The low survival rates associated with PDAC primarily reflect the fact that tumours progress rapidly with few specific symptoms and are thus at an advanced stage at diagnosis in most patients. As a result, there is an urgent need to develop accurate markers of pre-invasive pancreatic neoplasms in order to facilitate prediction of cancer risk and to help diagnose the disease at an earlier stage. However, screening for early diagnosis of prostate cancer remains challenging and identifying a highly accurate, low-cost screening test for early PDAC for use in clinical practice remains an important unmet need. More effective therapies are also crucial in PDAC, since progress in identifying novel therapies has been hampered by the genetic complexity of the disease and treatment remains a major challenge. Presently, the greatest step towards improved treatment efficacy has been made in the field of palliative chemotherapy by introducing FOLFIRINOX (folinic acid, 5-fluorouracil, irinotecan and oxaliplatin) and gemcitabine/nab-paclitaxel. Strategies designed to raise the profile of PDAC in research and clinical practice are a further requirement in order to ensure the best treatment for patients. This article proposes a number of approaches that may help to accelerate progress in treating patients with PDAC, which, in turn, may be expected to improve the quality of life and survival for those suffering from this devastating disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590
Jemal, A., Bray, F., Center, M. M., Ferlay, J., Ward, E., & Forman, D. (2011) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.20107 · Cited by 54,679
Global Cancer Statistics, 2002
Parkin, D. M., Bray, F., Ferlay, J., & Pisani, P. (2005) · CA: A Cancer Journal for Clinicians · doi:10.3322/canjclin.55.2.74 · Cited by 18,196
Siegel, R., Naishadham, D., & Jemal, A. (2013) · CA A Cancer Journal for Clinicians · doi:10.3322/caac.21166 · Cited by 11,825
FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer
Conroy, T., Desseigne, F., Ychou, M., Bouché, O., Guimbaud, R., Bécouarn, Y., Adenis, A., Raoul, J.-L., Gourgou-Bourgade, S., de la Fouchardière, C., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1011923 · Cited by 7,810
Early Palliative Care for Patients with Metastatic Non–Small-Cell Lung Cancer
Temel, J. S., Greer, J. A., Muzikansky, A., Gallagher, E. R., Admane, S., Jackson, V. A., Dahlin, C. M., Blinderman, C. D., Jacobsen, J., Pirl, W. F., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1000678 · Cited by 7,482
Spencer, P. M., Cameron, J. L., & Lin, L. (2000) · Cited by 7,202
Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
Von Hoff, D. D., Ervin, T., Arena, F. P., Chiorean, E. G., Infante, J., Moore, M., Seay, T., Tjulandin, S. A., Ma, W. W., Saleh, M. N., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1304369 · Cited by 6,712
Self-citationNivolumab plus Ipilimumab in Advanced Melanoma
Wolchok, J. D., Kluger, H., Callahan, M. K., Postow, M. A., Rizvi, N. A., Lesokhin, A. M., Segal, N. H., Ariyan, C. E., Gordon, R.-A., Reed, K., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1302369 · Cited by 4,230
Core Signaling Pathways in Human Pancreatic Cancers Revealed by Global Genomic Analyses
Jones, S., Zhang, X., Parsons, D. W., Lin, J. C.-H., Leary, R. J., Angenendt, P., Mankoo, P., Carter, H., Kamiyama, H., Jimeno, A., et al. (2008) · Science · doi:10.1126/science.1164368 · Cited by 3,969
Self-citationMoore, M. J., Goldstein, D., Hamm, J., Figer, A., Hecht, J. R., Gallinger, S., Au, H. J., Murawa, P., Walde, D., Wolff, R. A., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.07.9525 · Cited by 3,848
Identification of Pancreatic Cancer Stem Cells
Li, C., Heidt, D. G., Dalerba, P., Burant, C. F., Zhang, L., Adsay, V., Wicha, M., Clarke, M. F., & Simeone, D. M. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-2030 · Cited by 3,339
Olive, K. P., Jacobetz, M. A., Davidson, C. J., Gopinathan, A., McIntyre, D., Honess, D., Madhu, B., Goldgraben, M. A., Caldwell, M. E., Allard, D., et al. (2009) · Science · doi:10.1126/science.1171362 · Cited by 3,170
A Randomized Trial of Chemoradiotherapy and Chemotherapy after Resection of Pancreatic Cancer
Neoptolemos, J. P., Stocken, D. D., Friess, H., Bassi, C., Dunn, J. A., Hickey, H., Beger, H., Fernandez-Cruz, L., Dervenis, C., Lacaine, F., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032295 · Cited by 2,716
Self-citationDistant metastasis occurs late during the genetic evolution of pancreatic cancer
Yachida, S., Jones, S., Bozic, I., Antal, T., Leary, R., Fu, B., Kamiyama, M., Hruban, R. H., Eshleman, J. R., Nowak, M. A., et al. (2010) · Nature · doi:10.1038/nature09515 · Cited by 2,502
Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse
Hingorani, S. R., Petricoin, E. F., Maitra, A., Rajapakse, V., King, C., Jacobetz, M. A., Ross, S., Conrads, T. P., Veenstra, T. D., Hitt, B. A., et al. (2003) · Cancer Cell · doi:10.1016/s1535-6108(03)00309-x · Cited by 2,471
DPC4 , A Candidate Tumor Suppressor Gene at Human Chromosome 18q21.1
Hahn, S. A., Schutte, M., Shamsul Hoque, A. T. M., Moskaluk, C. A., da Costa, L. T., Rozenblum, E., Weinstein, C. L., Fischer, A., Yeo, C. J., Hruban, R. H., et al. (1996) · Science · doi:10.1126/science.271.5247.350 · Cited by 2,337 · cited 1×
“SMAD4 inactivation is a late event present in 50 e 60% of tumours and may be associated with more aggressive disease [27,28].”
Provenzano, P. P., Cuevas, C., Chang, A. E., Goel, V. K., Von Hoff, D. D., & Hingorani, S. R. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.01.007 · Cited by 2,195 · cited 1×
“…inhibition of TGF-b , which plays a key role in stroma formation, the Notch/Hedgehog pathway and use of pegylated hyaluronidase to decrease intra-tumoural pressure and increase vascularization, though phase II trials with the latter were halted due to unexpected adverse events [107,109,110].”
Stromal Elements Act to Restrain, Rather Than Support, Pancreatic Ductal Adenocarcinoma
Rhim, A. D., Oberstein, P. E., Thomas, D. H., Mirek, E. T., Palermo, C. F., Sastra, S. A., Dekleva, E. N., Saunders, T., Becerra, C. P., Tattersall, I. W., et al. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.04.021 · Cited by 2,085
Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes
Initiative, A. P. C. G., Biankin, A. V., Waddell, N., Kassahn, K. S., Gingras, M.-C., Muthuswamy, L. B., Johns, A. L., Miller, D. K., Wilson, P. J., Patch, A.-M., et al. (2012) · Nature · doi:10.1038/nature11547 · Cited by 2,058 · cited 4×
“Key genes mutated in the majority of PDAC tumours include KRAS , TP53 , SMAD4 and CDKN2A [22,23].”
InfluentialOettle, H., Neuhaus, P., Hochhaus, A., Hartmann, J. T., Gellert, K., Ridwelski, K., Niedergethmann, M., Zülke, C., Fahlke, J., Arning, M. B., et al. (2013) · JAMA · doi:10.1001/jama.2013.279201 · Cited by 1,794
CD40 Agonists Alter Tumor Stroma and Show Efficacy Against Pancreatic Carcinoma in Mice and Humans
Beatty, G. L., Chiorean, E. G., Fishman, M. P., Saboury, B., Teitelbaum, U. R., Sun, W., Huhn, R. D., Song, W., Li, D., Sharp, L. L., et al. (2011) · Science · doi:10.1126/science.1198443 · Cited by 1,672
Gillen, S., Schuster, T., Meyer zum Büschenfelde, C., Friess, H., & Kleeff, J. (2010) · PLoS Medicine · doi:10.1371/journal.pmed.1000267 · Cited by 1,552
Self-citationPancreatic Cancer: Adjuvant Combined Radiation and Chemotherapy Following Curative Resection
Kaiser, M. H. (1985) · Archives of Surgery · doi:10.1001/archsurg.1985.01390320023003 · Cited by 1,406
Neoptolemos, J. P., Stocken, D. D., Bassi, C., Ghaneh, P., Cunningham, D., Goldstein, D., Padbury, R., Moore, M. J., Gallinger, S., Mariette, C., et al. (2010) · JAMA · doi:10.1001/jama.2010.1275 · Cited by 1,397
Self-citationREporting recommendations for tumour MARKer prognostic studies (REMARK).
for the Statistics Subcommittee of the NCI-EORTC Working Group on Cancer Diagnostics, McShane, L. M., Altman, D. G., Sauerbrei, W., Taube, S. E., Gion, M., & Clark, G. M. (2005) · British Journal of Cancer · doi:10.1038/sj.bjc.6602678 · Cited by 1,394
The patterns and dynamics of genomic instability in metastatic pancreatic cancer
Campbell, P. J., Yachida, S., Mudie, L. J., Stephens, P. J., Pleasance, E. D., Stebbings, L. A., Morsberger, L. A., Latimer, C., McLaren, S., Lin, M.-L., et al. (2010) · Nature · doi:10.1038/nature09460 · Cited by 1,317
The Pancreas Cancer Microenvironment
Feig, C., Gopinathan, A., Neesse, A., Chan, D. S., Cook, N., & Tuveson, D. A. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-3114 · Cited by 1,316
Klinkenbijl, J. H., Jeekel, J., Sahmoud, T., van Pel, R., Couvreur, M. L., Veenhof, C. H., Arnaud, J. P., Gonzalez, D. G., de Wit, L. T., Hennipman, A., et al. (1999) · Annals of Surgery · doi:10.1097/00000658-199912000-00006 · Cited by 1,286
Neoptolemos, J., Dunn, J., Stocken, D., Almond, J., Link, K., Beger, H., Bassi, C., Falconi, M., Pederzoli, P., Dervenis, C., et al. (2001) · The Lancet · doi:10.1016/s0140-6736(01)06651-x · Cited by 1,111
Self-citationIacobuzio-Donahue, C. A., Fu, B., Yachida, S., Luo, M., Abe, H., Henderson, C. M., Vilardell, F., Wang, Z., Keller, J. W., Banerjee, P., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.17.7188 · Cited by 1,081 · cited 3×
“SMAD4 inactivation is a late event present in 50 e 60% of tumours and may be associated with more aggressive disease [27,28].”
Self-citationVon Hoff, D. D., Ramanathan, R. K., Borad, M. J., Laheru, D. A., Smith, L. S., Wood, T. E., Korn, R. L., Desai, N., Trieu, V., Iglesias, J. L., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.36.5742 · Cited by 1,044
Self-citationLouvet, C., Labianca, R., Hammel, P., Lledo, G., Zampino, M. G., André, T., Zaniboni, A., Ducreux, M., Aitini, E., Taïeb, J., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.06.023 · Cited by 950
Self-citationCallery, M. P., Chang, K. J., Fishman, E. K., Talamonti, M. S., William Traverso, L., & Linehan, D. C. (2009) · Annals of Surgical Oncology · doi:10.1245/s10434-009-0408-6 · Cited by 902
Loehrer, P. J., Feng, Y., Cardenes, H., Wagner, L., Brell, J. M., Cella, D., Flynn, P., Ramanathan, R. K., Crane, C. H., Alberts, S. R., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.34.8904 · Cited by 830
Cunningham, D., Chau, I., Stocken, D. D., Valle, J. W., Smith, D., Steward, W., Harper, P. G., Dunn, J., Tudur-Smith, C., West, J., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.24.2446 · Cited by 823
Self-citationDevelopment of PI3K inhibitors: lessons learned from early clinical trials
Rodon, J., Dienstmann, R., Serra, V., & Tabernero, J. (2013) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2013.10 · Cited by 766
Regine, W. F., Winter, K. A., Abrams, R. A., Safran, H., Hoffman, J. P., Konski, A., Benson, A. B., Macdonald, J. S., Kudrimoti, M. R., Fromm, M. L., et al. (2008) · JAMA · doi:10.1001/jama.299.9.1019 · Cited by 755
Evans, D. B., Varadhachary, G. R., Crane, C. H., Sun, C. C., Lee, J. E., Pisters, P. W. T., Vauthey, J.-N., Wang, H., Cleary, K. R., Staerkel, G. A., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.15.8634 · Cited by 731
Berlin, J. D., Catalano, P., Thomas, J. P., Kugler, J. W., Haller, D. G., & Benson, A. B. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.11.149 · Cited by 729
Gastrointestinal Tumor Study Group (1987) · Cancer · doi:10.1002/1097-0142(19870615)59:12<2006::aid-cncr2820591206>3.0.co;2-b · Cited by 714
Temel, J. S., Greer, J. A., Admane, S., Gallagher, E. R., Jackson, V. A., Lynch, T. J., Lennes, I. T., Dahlin, C. M., & Pirl, W. F. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.32.4459 · Cited by 696
Chauffert, B., Mornex, F., Bonnetain, F., Rougier, P., Mariette, C., Bouché, O., Bosset, J. F., Aparicio, T., Mineur, L., Azzedine, A., et al. (2008) · Annals of Oncology · doi:10.1093/annonc/mdn281 · Cited by 696
Heinemann, V., Quietzsch, D., Gieseler, F., Gonnermann, M., Schönekäs, H., Rost, A., Neuhaus, H., Haag, C., Clemens, M., Heinrich, B., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.05.1490 · Cited by 683
Self-citationBachem, M. G., Schünemann, M., Ramadani, M., Siech, M., Beger, H., Buck, A., Zhou, S., Schmid-Kotsas, A., & Adler, G. (2005) · Gastroenterology · doi:10.1053/j.gastro.2004.12.036 · Cited by 657
Most Pancreatic Cancer Resections are R1 Resections
Esposito, I., Kleeff, J., Bergmann, F., Reiser, C., Herpel, E., Friess, H., Schirmacher, P., & Büchler, M. W. (2008) · Annals of Surgical Oncology · doi:10.1245/s10434-008-9839-8 · Cited by 645
Self-citationStudy Group of Surgical Adjuvant Therapy for Carcinomas of the Pancreas and Biliary Tract, Takada, T., Amano, H., Yasuda, H., Nimura, Y., Matsushiro, T., Kato, H., Nagakawa, T., & Nakayama, T. (2002) · Cancer · doi:10.1002/cncr.10831 · Cited by 631
Neoptolemos, J. P., Moore, M. J., Cox, T. F., Valle, J. W., Palmer, D. H., McDonald, A. C., Carter, R., Tebbutt, N. C., Dervenis, C., Smith, D., et al. (2012) · JAMA · doi:10.1001/jama.2012.7352 · Cited by 597
Self-citationEGF Receptor Is Required for KRAS-Induced Pancreatic Tumorigenesis
Ardito, C. M., Grüner, B. M., Takeuchi, K. K., Lubeseder-Martellato, C., Teichmann, N., Mazur, P. K., DelGiorno, K. E., Carpenter, E. S., Halbrook, C. J., Hall, J. C., et al. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.07.024 · Cited by 517
Farrell, J. J., Elsaleh, H., Garcia, M., Lai, R., Ammar, A., Regine, W. F., Abrams, R., Benson, A. B., Macdonald, J., Cass, C. E., et al. (2009) · Gastroenterology · doi:10.1053/j.gastro.2008.09.067 · Cited by 458
Valle, J. W., Palmer, D., Jackson, R., Cox, T., Neoptolemos, J. P., Ghaneh, P., Rawcliffe, C. L., Bassi, C., Stocken, D. D., Cunningham, D., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.50.7657 · Cited by 455
Self-citationMeta-Analyses of Chemotherapy for Locally Advanced and Metastatic Pancreatic Cancer
Sultana, A., Smith, C. T., Cunningham, D., Starling, N., Neoptolemos, J. P., & Ghaneh, P. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.09.2551 · Cited by 442
Self-citationUeno, H., Kosuge, T., Matsuyama, Y., Yamamoto, J., Nakao, A., Egawa, S., Doi, R., Monden, M., Hatori, T., Tanaka, M., et al. (2009) · British Journal of Cancer · doi:10.1038/sj.bjc.6605256 · Cited by 439
Poplin, E., Feng, Y., Berlin, J., Rothenberg, M. L., Hochster, H., Mitchell, E., Alberts, S., O'Dwyer, P., Haller, D., Catalano, P., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.20.9007 · Cited by 438
Heinemann, V., Boeck, S., Hinke, A., Labianca, R., & Louvet, C. (2008) · BMC Cancer · doi:10.1186/1471-2407-8-82 · Cited by 434
Self-citationErkan, M., Michalski, C. W., Rieder, S., Reiser–Erkan, C., Abiatari, I., Kolb, A., Giese, N. A., Esposito, I., Friess, H., & Kleeff, J. (2008) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2008.05.006 · Cited by 424
Self-citationInfante, J. R., Matsubayashi, H., Sato, N., Tonascia, J., Klein, A. P., Riall, T. A., Yeo, C., Iacobuzio-Donahue, C., & Goggins, M. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.07.8824 · Cited by 406
Richter, A., Niedergethmann, M., Sturm, J. W., Lorenz, D., Post, S., & Trede, M. (2003) · World Journal of Surgery · doi:10.1007/s00268-002-6659-z · Cited by 401
EGF Receptor Signaling Is Essential for K-Ras Oncogene-Driven Pancreatic Ductal Adenocarcinoma
Navas, C., Hernández-Porras, I., Schuhmacher, A. J., Sibilia, M., Guerra, C., & Barbacid, M. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.08.001 · Cited by 391
Seufferlein, T., Bachet, J. B., Van Cutsem, E., & Rougier, P. (2012) · Annals of Oncology · doi:10.1093/annonc/mds224 · Cited by 389
Colucci, G., Giuliani, F., Gebbia, V., Biglietto, M., Rabitti, P., Uomo, G., Cigolari, S., Testa, A., Maiello, E., & Lopez, M. (2002) · PubMed · Cited by 384
Marsh, R., Talamonti, M. S., & Ji, Y. (2013) · Translational gastrointestinal cancer · Cited by 377
Eser, S., Reiff, N., Messer, M., Seidler, B., Gottschalk, K., Dobler, M., Hieber, M., Arbeiter, A., Klein, S., Kong, B., et al. (2013) · Cancer Cell · doi:10.1016/j.ccr.2013.01.023 · Cited by 360
Löhr, M., Klöppel, G., Maisonneuve, P., Lowenfels, A. B., & Lüttges, J. (2005) · Neoplasia · doi:10.1593/neo.04445 · Cited by 343 · cited 1×
“KRAS is an early mutation occurring in PanIN-1A lesions, suggesting that this alteration may play an important role in the initiation of many PDACs [6,24].”
Self-citationPancreatic Cancer hENT1 Expression and Survival From Gemcitabine in Patients From the ESPAC-3 Trial
Greenhalf, W., Ghaneh, P., Neoptolemos, J. P., Palmer, D. H., Cox, T. F., Lamb, R. F., Garner, E., Campbell, F., Mackey, J. R., Costello, E., et al. (2014) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djt347 · Cited by 337
Self-citationPancreatic adenocarcinomas frequently show p53 gene mutations.
Scarpa, A., Capelli, P., Mukai, K., Zamboni, G., Oda, T., Iacono, C., & Hirohashi, S. (1993) · PubMed · Cited by 332
Löhr, M. J., Schmidt, C., Ringel, J., Kluth, M., Müller, P., Nizze, H., & Jesnowski, R. (2001) · PubMed · Cited by 325
Colucci, G., Giuliani, F., Gebbia, V., Biglietto, M., Rabitti, P., Uomo, G., Cigolari, S., Testa, A., Maiello, E., & Lopez, M. (2002) · Cancer · doi:10.1002/cncr.10323 · Cited by 307
Colucci, G., Labianca, R., Di Costanzo, F., Gebbia, V., Cartenì, G., Massidda, B., Dapretto, E., Manzione, L., Piazza, E., Sannicolò, M., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.25.4433 · Cited by 304
Self-citationLaethem, J. V., Hammel, P. R., Mornex, F., Azria, D., van Tienhoven, G., Vergauwe, P. L., Peeters, M., Polus, M., Praet, M., Mauer, M. E. L., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.30.3446 · Cited by 299
Tada, M., Ohashi, M., Shiratori, Y., Okudaira, T., Komatsu, Y., Kawabe, T., Yoshida, H., Machinami, R., Kishi, K., & Omata, M. (1996) · Gastroenterology · doi:10.1053/gast.1996.v110.pm8536861 · Cited by 288
Crane, C. H., Varadhachary, G. R., Yordy, J. S., Staerkel, G. A., Javle, M. M., Safran, H., Haque, W., Hobbs, B. D., Krishnan, S., Fleming, J. B., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.33.8038 · Cited by 288
Surgical treatment of pancreatic adenocarcinoma
Kuhlmann, K. F. D., de Castro, S. M. M., Wesseling, J. G., ten Kate, F. J. W., Offerhaus, G. J. A., Busch, O. R. C., van Gulik, T. M., Obertop, H., & Gouma, D. J. (2004) · European Journal of Cancer · doi:10.1016/j.ejca.2003.10.026 · Cited by 286
Faris, J. E., Blaszkowsky, L. S., McDermott, S., Guimaraes, A. R., Szymonifka, J., Huynh, M. A., Ferrone, C. R., Wargo, J. A., Allen, J. N., Dias, L. E., et al. (2013) · The Oncologist · doi:10.1634/theoncologist.2012-0435 · Cited by 278
Pancreatic cancer–associated stroma production
Korc, M. (2007) · The American Journal of Surgery · doi:10.1016/j.amjsurg.2007.05.004 · Cited by 268
Campbell, F., Smith, R. A., Whelan, P., Sutton, R., Raraty, M., Neoptolemos, J. P., & Ghaneh, P. (2009) · Histopathology · doi:10.1111/j.1365-2559.2009.03376.x · Cited by 258
Self-citationCouvelard, A., O'Toole, D., Turley, H., Leek, R., Sauvanet, A., Degott, C., Ruszniewski, P., Belghiti, J., Harris, A. L., Gatter, K., et al. (2005) · British Journal of Cancer · doi:10.1038/sj.bjc.6602245 · Cited by 257
Screening for Pancreatic Cancer: Why, How, and Who?
Poruk, K. E., Firpo, M. A., Adler, D. G., & Mulvihill, S. J. (2013) · Annals of Surgery · doi:10.1097/sla.0b013e31825ffbfb · Cited by 249
Maréchal, R., Bachet, J., Mackey, J. R., Dalban, C., Demetter, P., Graham, K., Couvelard, A., Svrcek, M., Bardier–Dupas, A., Hammel, P., et al. (2012) · Gastroenterology · doi:10.1053/j.gastro.2012.06.006 · Cited by 241
Self-citationHuguet, F., Girard, N., Guerche, C. S.-E., Hennequin, C., Mornex, F., & Azria, D. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.19.7921 · Cited by 236
Permuth-Wey, J., & Egan, K. M. (2009) · Familial Cancer · doi:10.1007/s10689-008-9214-8 · Cited by 232
Liao, W.-C., Chien, K.-L., Lin, Y.-L., Wu, M.-S., Lin, J.-T., Wang, H.-P., & Tu, Y.-K. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70388-7 · Cited by 229
Pancreatic cancer microenvironment
Kleeff, J., Beckhove, P., Esposito, I., Herzig, S., Huber, P. E., Löhr, J. M., & Friess, H. (2007) · International Journal of Cancer · doi:10.1002/ijc.22871 · Cited by 225
Self-citationEarly Diagnosis of Pancreatic Cancer: Challenges and New Developments
Kaur, S., Baine, M. J., Jain, M., Sasson, A. R., & Batra, S. K. (2012) · Biomarkers in Medicine · doi:10.2217/bmm.12.69 · Cited by 220
Shi, C., Hruban, R. H., & Klein, A. P. (2009) · Archives of Pathology & Laboratory Medicine · doi:10.5858/133.3.365 · Cited by 212
García-Manteiga, J. M., Molina‐Arcas, M., Casado, F. J., Mazo, A., & Pastor‐Anglada, M. (2003) · PubMed · Cited by 211
for the European Study Group of Pancreatic Cancer, Neoptolemos, J. P., Stocken, D. D., Tudur Smith, C., Bassi, C., Ghaneh, P., Owen, E., Moore, M., Padbury, R., Doi, R., et al. (2009) · British Journal of Cancer · doi:10.1038/sj.bjc.6604838 · Cited by 204
Self-citationPrecursors to Pancreatic Cancer
Hruban, R. H., Maitra, A., Kern, S. E., & Goggins, M. (2007) · Gastroenterology Clinics of North America · doi:10.1016/j.gtc.2007.08.012 · Cited by 203
Murphy, S. J., Hart, S. N., Lima, J. F., Kipp, B. R., Klebig, M., Winters, J. L., Szabo, C., Zhang, L., Eckloff, B. W., Petersen, G. M., et al. (2013) · Gastroenterology · doi:10.1053/j.gastro.2013.07.049 · Cited by 199
PALB2/FANCN: Recombining Cancer and Fanconi Anemia
Tischkowitz, M., & Xia, B. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-1012 · Cited by 198
New biomarkers and targets in pancreatic cancer and their application to treatment
Costello, E., Greenhalf, W., & Neoptolemos, J. P. (2012) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2012.119 · Cited by 195
Self-citationUnderstanding Metastasis in Pancreatic Cancer: A Call for New Clinical Approaches
Tuveson, D. A., & Neoptolemos, J. P. (2012) · Cell · doi:10.1016/j.cell.2011.12.021 · Cited by 188
Self-citationScheithauer, W., Schüll, B., Ulrich-Pur, H., Schmid, K., Raderer, M., Haider, K., Kwasny, W., Depisch, D., Schneeweiss, B., Lang, F., et al. (2003) · Annals of Oncology · doi:10.1093/annonc/mdg029 · Cited by 187
Sideras, K., Braat, H., Kwekkeboom, J., van Eijck, C. H., Peppelenbosch, M. P., Sleijfer, S., & Bruno, M. (2014) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2013.11.005 · Cited by 173
Imaging of pancreatic cancer: An overview.
Tummala, P., Junaidi, O., & Agarwal, B. (2011) · PubMed · doi:10.3978/j.issn.2078-6891.2011.036 · Cited by 149
Pancreatic Cancer Stem Cells: Implications for the Treatment of Pancreatic Cancer
Simeone, D. M. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0584 · Cited by 146
Oncogenic K-Ras requires activation for enhanced activity
Huang, H., Daniluk, J., Liu, Y., Chu, J., Li, Z., Ji, B., & Logsdon, C. D. (2013) · Oncogene · doi:10.1038/onc.2012.619 · Cited by 145
Xia, J., Duan, Q., Ahmad, A., Bao, B., Banerjee, S., Shi, Y., Ma, J., Geng, J., Chen, Z., Rahman, K. W., et al. (2012) · Current Drug Targets · doi:10.2174/138945012804545597 · Cited by 144
Pelzer, U., Kubica, K., Stieler, J., Schwaner, I., Heil, G., Görner, M., Mölle, M., Hilbig, A., Dörken, B., Riess, H. B., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.26.15_suppl.4508 · Cited by 127
Gamma secretase inhibition promotes hypoxic necrosis in mouse pancreatic ductal adenocarcinoma
Cook, N., Frese, K. K., Bapiro, T. E., Jacobetz, M. A., Gopinathan, A., Miller, J. L., Rao, S. S., Demuth, T., Howat, W., Jodrell, D. I., et al. (2012) · The Journal of Experimental Medicine · doi:10.1084/jem.20111923 · Cited by 103
Osteonectin Influences Growth and Invasion of Pancreatic Cancer Cells
Guweidhi, A., Kleeff, J. H., Adwan, H., et al. (2005) · Annals of Surgery · doi:10.1097/01.sla.0000171866.45848.68 · Cited by 101
Self-citationCostanzo, F. D., Carlini, P., Doni, L., Massidda, B., Mattioli, R., Iop, A., Barletta, E., Moscetti, L. I., Recchia, F., Tralongo, P., et al. (2005) · British Journal of Cancer · doi:10.1038/sj.bjc.6602640 · Cited by 101
Real, F. X. (2003) · Gastroenterology · doi:10.1016/s0016-5085(03)00389-5 · Cited by 99
Self-citationMolecular pathways in pancreatic carcinogenesis
Macgregor‐Das, A. M., & Iacobuzio–Donahue, C. A. (2012) · Journal of Surgical Oncology · doi:10.1002/jso.23213 · Cited by 99
Rajeshkumar, N. V., Rasheed, Z. A., García-García, E., López‐Ríos, F., Fujiwara, K., Matsui, W. H., & Hidalgo, M. M. (2010) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-10-0370 · Cited by 99
Self-citationZaniboni, A., Aitini, E., Barni, S., Ferrari, D., Cascinu, S., Catalano, V., Valmadre, G., Ferrara, D., Veltri, E. M., Codignola, C., et al. (2012) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-012-1875-1 · Cited by 90
Self-citationNeoadjuvant Therapy of Pancreatic Cancer: The Emerging Paradigm?
Lim, K., Chung, E., Khan, A. S., Cao, D., Linehan, D. C., Ben‐Josef, E., & Wang‐Gillam, A. (2012) · The Oncologist · doi:10.1634/theoncologist.2011-0268 · Cited by 87
Hammel, P. R., Huguet, F., Laethem, J. V., Goldstein, D., Glimelius, B. L. G., Artru, P., Borbath, I., Bouché, O., Shannon, J., André, T., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2013.31.18_suppl.lba4003 · Cited by 86
Translational Therapeutic Opportunities in Ductal Adenocarcinoma of the Pancreas
Hidalgo, M. M., & Hoff, D. D. V. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-1327 · Cited by 83
Self-citationDahan, L., Bonnetain, F., Ychou, M., Mitry, E., Gasmi, M., Raoul, J., Cattan, S., Phelip, J., Hammel, P. R., Chauffert, B., et al. (2010) · Gut · doi:10.1136/gut.2010.216135 · Cited by 81
Genetically Defined Subsets of Human Pancreatic Cancer Show Unique In Vitro Chemosensitivity
Cui, Y., Brosnan‐Cashman, J. A., Blackford, A. L., Sur, S., Hruban, R. H., Kinzler, K. W., Vogelstein, B., Maitra, A., Diaz, L. A., Iacobuzio–Donahue, C. A., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-0827 · Cited by 80
Bachet, J., Maréchal, R., Demetter, P., Bonnetain, F., Couvelard, A., Svrcek, M., Bardier–Dupas, A., Hammel, P. R., Sauvanet, A., Louvet, C., et al. (2012) · Annals of Oncology · doi:10.1093/annonc/mdr617 · Cited by 78
Alterations of tumor suppressor gene p16 INK4a in pancreatic ductal carcinoma
Attri, J., Srinivasan, R., Majumdar, S., Radotra, B. D., & Wig, J. D. (2005) · BMC Gastroenterology · doi:10.1186/1471-230x-5-22 · Cited by 74
Potential Targets for Pancreatic Cancer Immunotherapeutics
Dodson, L. F., Hawkins, W. G., & Goedegebuure, P. S. (2011) · Immunotherapy · doi:10.2217/imt.11.10 · Cited by 74
Detection of pancreatic cancer tumours and precursor lesions by cathepsin E activity in mouse models
Cruz‐Monserrate, Z., Abd‐Elgaliel, W. R., Grote, T., Deng, D., Ji, B., Arumugam, T., Wang, H., Tung, C., & Logsdon, C. D. (2011) · Gut · doi:10.1136/gutjnl-2011-300544 · Cited by 74
Germline BRCA1 mutations predispose to pancreatic adenocarcinoma
Al-Sukhni, W., Rothenmund, H., Borgida, A., Zogopoulos, G., O’Shea, A.-M., Pollett, A. F., & Gallinger, S. (2008) · Human Genetics · doi:10.1007/s00439-008-0554-0 · Cited by 67
Is it possible to survive pancreatic cancer?
Löhr, M. J. (2006) · Nature Clinical Practice Gastroenterology & Hepatology · doi:10.1038/ncpgasthep0469 · Cited by 56
Fukutomi, A., Uesaka, K., Boku, N., Kanemoto, H., Konishi, M., Matsumoto, I., Kaneoka, Y., Shimizu, Y., Nakamori, S., Sakamoto, H., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2013.31.15_suppl.4008 · Cited by 51
Zhu, K., Qin, H., Cha, S.-C., Neelapu, S. S., Overwijk, W. W., Lizee, G. A., Abbruzzese, J. L., Hwu, P., Radvanyi, L. G., Kwak, L. W., et al. (2007) · Vaccine · doi:10.1016/j.vaccine.2007.08.050 · Cited by 51
Pancreatic Cancer Development and Progression: Remodeling the Model
Real, F. X., Cibrián–Uhalte, E., & Martinelli, P. (2008) · Gastroenterology · doi:10.1053/j.gastro.2008.07.033 · Cited by 49
Self-citationGenetics and pathology of pancreatic cancer
Winter, J. M., Maitra, A., & Yeo, C. J. (2006) · HPB · doi:10.1080/13651820600804203 · Cited by 48
Screening for Pancreatic Cancer
Ngamruengphong, S., & Canto, M. I. (2016) · Surgical Clinics of North America · doi:10.1016/j.suc.2016.07.016 · Cited by 34
Abstract PR11: Egfr is essential for Ras-driven pancreatic cancer development
Grüner, B. M., Lubeseder–Martellato, C., von Briel, T., Mazur, P. K., Schmid, R. M., & Siveke, J. T. (2011) · Cancer Research · doi:10.1158/1538-7445.fbcr11-pr11 · Cited by 1
Cited by
Epidemiology of Pancreatic Cancer: Global Trends, Etiology and Risk Factors
Rawla, P., Sunkara, T., & Gaduputi, V. (2019) · World Journal of Oncology · doi:10.14740/wjon1166 · Cited by 2,269
Epidemiology of pancreatic cancer
Ilic, M., & Ilic, I. (2016) · World Journal of Gastroenterology · doi:10.3748/wjg.v22.i44.9694 · Cited by 1,301
O’Reilly, E. M., Oh, D.-Y., Dhani, N., Renouf, D. J., Lee, M. A., Sun, W., Fisher, G., Hezel, A., Chang, S.-C., Vlahovic, G., et al. (2019) · JAMA Oncology · doi:10.1001/jamaoncol.2019.1588 · Cited by 767
Rice, A. J., Cortes, E., Lachowski, D., Cheung, B. C. H., Karim, S. A., Morton, J. P., & del Río Hernández, A. (2017) · Oncogenesis · doi:10.1038/oncsis.2017.54 · Cited by 523
Karamitopoulou, E. (2019) · British Journal of Cancer · doi:10.1038/s41416-019-0479-5 · Cited by 301
Metadata
- Authors
- Hidalgo, M., Cascinu, S., Kleeff, J., Labianca, R., Löhr, J.-M., Neoptolemos, J., Real, F. X., Van Laethem, J.-L., & Heinemann, V.
- Venue
- Pancreatology
- Publisher
- Elsevier BV
- Published
- 2015-01
- Volume
- 15
- Issue
- 1
- Pages
- 8-18
- ISSN
- 1424-3903 (ISSN-L)
- OpenAlex
- W2039225116
- Cited by
- 509
- References
- 123
- FWCI
- 12.49
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.